RPG Life Sciences Ltd

Meeting Details

• Date and time: August 25, 2026, 10:00 IST onwards.

Venue and Format

• Venue/Mode: Mumbai, physical meeting.
• Nature of meeting: Group meet.

Event/Availability

• Event: Antique Healthcare Investor Conference 2026.
• Presentation, if any, will be available on the company/stock exchange websites.

Cessation: Senior Management

• Deepak Shukla ceased as Senior Management on Aug 14, 2026, for appointment as CEO of RPG Active Pharma.

Transaction overview

• Purpose: subscribe in rights issue of RPG Active Pharma Limited, a wholly owned subsidiary.
• Investment amount: up to Rs 65,68,60,500 through cash remittance.
• Equity shares allotted: 21,89,535 at Re 10 face value.
• Date of allotment: August 14, 2026.

Ownership and subsidiary status

• Post-investment holding: RPG Life Sciences maintains 100% stake in RPGAP.
• RPGAP authorized capital Rs 7 crore; paid-up Rs 1.1685 crore; no turnover yet.

Related party and governance

• Related party: investment is arm's length; promoter group has no additional interest.

Regulatory and operational impact

• Regulatory approvals: not required.
• Impact: strengthens 100% subsidiary structure; no immediate turnover or operational change disclosed.

API business transfer to subsidiary

• BTA-based transfer completed; RPG Active Pharma Limited owns the API business.
• Transfer is on slump sale basis.
• Effective date of transfer: August 15, 2026.
• Subsidiary is wholly owned by RPG Life Sciences.

Meeting Details

• Date: August 13, 2026.
• Time: 09:00 IST onwards.
• Details/Host: Emkay Confluence 2026.
• Venue/Mode: Mumbai, Physical.
• Nature: Group Meet.

Purpose

• Purpose: Analyst/Institutional investor meet.

Availability of Materials

• Presentation, if any, will be available on company/stock exchange websites.

Business Overview

• Integrated pharma company with branded formulations, global generics, and synthetic APIs.
• API and Formulations manufacturing with dedicated immunosuppressant MF2 unit.
• Global presence in 50+ markets; EU/TGA/PMDA-compliant plants.
• Immunosuppressants leadership anchored by Azathioprine; Naprosyn expansion toward 100 crore.
• Five pillars drive profitable domestic growth and global expansion.
• Capex of Rs 185+ crore since FY22 supports modern plant capacity.

Key Operational Highlights

• Q1 FY27 revenue from operations Rs 195.7 crore, +15.8% YoY.
• DF revenue Rs 132.5 crore; +14.8% YoY.
• IF revenue Rs 35.0 crore; +7.7% YoY.
• API revenue Rs 26.6 crore; +35.6% YoY.
• DF share 68.3%, IF 18.0%, API 13.7% of total sales.
• EBITDA Rs 30.8 crore; margin 15.7%; +17.0%.
• PBT Rs 48.0 crore; margin 24.5%; +17.9%.
• PAT Rs 41.5 crore; margin 21.2%; +17.0%.
• ICRA reaffirmed long-term rating A+; short-term A1; outlook Stable.
• Healthy cash flows; strong balance sheet; no debt-funded capex.

Financial Performance

• Total revenue Rs 195.7 crore in Q1 FY27, +15.8% YoY.
• DF/IF/API mix outlines segment contributions to growth.
• EBITDA margin 15.7%; PAT margin 21.2%; robust profitability.
• PBT margin 24.5%; consistent margin expansion observed YoY.
• Segmental growth drivers include DF and API momentum.
• Credit metrics supported by healthy cash flows and stable balance sheet.

Capital Structure & Liquidity

• Capex Rs 185+ crore since FY22; capacity expansion and upgrades.
• No debt-funded capex; strong balance sheet and liquidity implied by cash flows.

Strategic Priorities & Outlook

• Five pillars: expand emerging markets and double-digit core brand growth.
• Immunosuppressant portfolio targeted at ₹200 crore; Naprosyn to ₹100 crore.
• Grow API business; evaluate growth opportunities under defined M&A framework.
• Digital roadmap to streamline front-end and back-end operations.
• Talent transformation via org reviews and skill development.
• State-of-art capacity, lab modernization, and productivity improvements.

Risks & Mitigation

• API block fire incident impacted growth; mitigated by new customer traction.

Governance & Leadership

• No board or leadership changes disclosed.

Financial highlights

• Revenue from operations ₹195.7 Cr, up 15.8% YoY.
• EBITDA ₹48.0 Cr, up 17.9% YoY.
• EBITDA margin 24.5%, up 40 bps YoY.

Domestic formulations performance

• Domestic Formulations grew 14.8% in Q1, vs market 11.6%.
• Naprosyn grew 16%; double-digit growth in nephrology and rheumatology.

Other segments

• International Formulations grew 7.7% in the quarter.
• API business grew 35.6% as unit back to operations.

Milestones

• Entered Top 50 Indian pharmaceutical companies in June 2026; 5th fastest growing in IPM.

Outlook and management commentary

• FY27 started with growth and profitability; focus on international expansion and API scaling.
• Strong balance sheet supports continuing growth; ongoing investment in talent.
• Recognitions: Top Nephrology Company-2026; Best Use of AI in Sales Force Effectiveness.

Financial results & audit

• Unaudited standalone results for quarter ended June 30, 2026 approved.
• Unaudited consolidated results for quarter ended June 30, 2026 approved.
• Limited Review Reports from SRBC & CO LLP accompany results.
• Auditors concluded no material misstatement in standalone results.
• Auditors concluded no material misstatement in consolidated results.
• Total exceptional items recognised as income: quarter Rs 110 lakhs; year Rs 390 lakhs.
• Insurance claim net income recognized on fire incident.
• Impact of New Labour Codes recognized; impairment of intangible assets under development.

Major actions & regulatory note

• API division to transfer to wholly owned subsidiary RPG Active Pharma Limited.
• Subsidiary RPG Active Pharma Limited incorporated December 24, 2025.
• Transfer is subject to requisite consents and regulatory approvals.
• Transaction expected to conclude on receipt of approvals and completion of conditions precedent.
• Regulatory update: impact from New Labour Codes recognized; ongoing monitoring.